OpenArc Corporate Advisory’s Puma Biotechnology PBYI Stock Holding History

OpenArc Corporate Advisory’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$482K	Sell	59,491 -30,000	-34%	-$220K	0.01%	495
2026 Q1	$572K	Buy	89,491 +130	+0.1%	+$838	0.01%	415
2025 Q4	$532K	Buy	+89,361	New	+$475K	0.01%	390

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OpenArc Corporate Advisory's PBYI Position: Q2 2026 in Review

OpenArc Corporate Advisory reduced its Puma Biotechnology (PBYI) stake by 34% in Q2 2026, selling an estimated $220K and leaving 59,491 shares worth $482K. The position accounts for 0.01% of the portfolio, ranked #495.

OpenArc Corporate Advisory first reported a position in PBYI in Q4 2025 and has held it in 3 quarters since. The position peaked at $572K in Q1 2026. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

OpenArc Corporate Advisory held 59,491 shares of Puma Biotechnology worth $482K as of Q2 2026.
OpenArc Corporate Advisory sold 30,000 Puma Biotechnology shares in Q2 2026, an estimated $220K.
Puma Biotechnology made up 0.01% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #495 holding.
OpenArc Corporate Advisory first reported a position in Puma Biotechnology in Q4 2025 and has held it in 3 quarters since.
OpenArc Corporate Advisory's Puma Biotechnology position peaked at $572K in Q1 2026.
160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.